The exploratory synthesis did not show a clear difference between MF59-adjuvanted and high-dose vaccines, but sensitivity to outcome selection, heterogeneity estimation and potentially overlapping populations limits interpretation.
Daniela Amicizia, F. Marchini, I. Schenone et al.· Vaccines· 0 citations
Evaluating the 2023/24 and 2024/25 influenza vaccination campaigns in Liguria (Italy) reveals a persistent mismatch between national recommendations and real-world clinical practice and only 65% and 73% among ≥65 y individuals received enhanced vaccines.
Daniela Amicizia, F. Grammatico, E. Massaro et al.· Human Vaccines & Immunothera...· 0 citations
Whether mRNA platforms offer incremental benefits over enhanced formulations (such as high-dose, adjuvanted, or recombinant vaccines), which are the preferred options in some countries for older adults, remains to be established.
A. Domnich, Andrea Orsi· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.